Wise named Cline Davis & Mann CEO

Share this article:
Ed Wise has been named CEO of Cline Davis & Mann (CDM), while Carol DiSanto will succeed Wise as president. The executive level moves, first announced today, follow the November retirement announcement made by CDM COO Jack Slonaker to pursue personal interests. Wise joined CDM in 1984 and was named president in 2001, helping diversify the Omnicom-owned agency's client roster by adding clients including Amgen, Novartis, NovoNordisk. DiSanto, a 15-year CDM veteran, served most recently as CDM director of client services, working on brands including the Pfizer blockbusters Lipitor and Viagra and Amgen’s Aranesp.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...